- Conditions
- Pharmacokinetics
- Interventions
- Colchicine, Verapamil HCl ER
- Drug
- Lead sponsor
- Mutual Pharmaceutical Company, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- East Grand Forks, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
- Interventions
- Brentuximab Vedotin, Cyclosporine, Pharmacokinetic Study, Verapamil, Verapamil Hydrochloride
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Type1 Diabetes
- Interventions
- Not listed
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more
- Conditions
- Healthy
- Interventions
- Verapamil Hydrochloride Extended-Release Capsules, 300 mg, Verelan® PM Extended-Release Capsules, 300 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Healthy
- Interventions
- Verapamil Hydrochloride Extended-Release Capsules, 300 mg, Verelan® PM Extended-Release Capsules, 300 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance
- Interventions
- Verapamil Hydrochloride
- Drug
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Providence, Rhode Island
- Conditions
- Sinusitis, Nasal Polyps
- Interventions
- Verapamil Hydrochloride Intranasal
- Drug
- Lead sponsor
- Benjamin Bleier
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Bexagliflozin, Probenecid, Rifampin, Verapamil
- Drug
- Lead sponsor
- Theracos
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Sinusitis, Nasal Polyps
- Interventions
- Verapamil HCl, Placebo
- Drug · Other
- Lead sponsor
- Benjamin Bleier
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- Verapamil HCL Extended-Release Capsules 300 mg, Verelan® PM Extended-Release Capsules 300 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Type1 Diabetes
- Interventions
- HCL, verapamil 120mg tablet, non-HCL, placebo
- Device · Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more
- Conditions
- Healthy
- Interventions
- Verapamil Hydrochloride Extended-Release Capsules, 300 mg, Verelan® PM Extended-Release Capsules, 300 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Healthy
- Interventions
- INX-08189 50 mg, 240 mg verapamil HCL ER, 50 mg dose of INX-08189 and 240 mg verapamil HCL ER
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
- Interventions
- Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 20
- States / cities
- La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more